Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

American Journal of Psychiatry

Volumn 155, Issue 1, 1998, Pages 36-42

  Ballenger, James C ^a,b   Wheadon, David E ^a   Steiner, Martin ^a   Bushnell, William ^a   Gergel, Ivan P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

ADULT; AGITATION; ANXIETY; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DYSMENORRHEA; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; TREMOR;

EID: 0031984862     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.1.36     Document Type: Article

References (34)

1. Ballenger JC: Selective serotonin reuptake inhibitors: their use in the treatment of panic disorder, in Selective Serotonin Reuptake Inhibitors: Advances in Basic Research and Clinical Practice, 2nd ed. Edited by Feighner JP, Boyer WF. New York, John Wiley & Sons, 1996, pp 155-178
2. Sheehan DV, Harnett-Sheehan K: The role of SSRIs in panic disorder. J Clin Psychiatry 1996; 57(suppl 10):51-58
3. Davidson J, Lydiard RB, McCann U, Pollack M, Rosenbaum JF: Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull 1995; 31:457-507
4. Dunbar GC: A double-blind placebo controlled study of paroxetine and clomipramine in the treatment of panic disorder, in 1995 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1995, p 157
5. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder: n randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167:374-379
6. Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50:44-50
7. Den Boer JA, Westenberg HG: Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3:59-74
8. Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13:321-326
9. German JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF: An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7:329-332
10. Schneier FR, Liebowitz MR, Davies SO, Fairbank J, Hollander E, Campeas R, Klein DF: Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10:119-121
11. Gorman JM, Wolkow R: Sertraline as a treatment for panic disorder (abstract). Neuropsychopharmacology 1994; 10(35, part 2): 1975
12. Marks IM, Matthews HM: Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17:263-267
13. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
14. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
15. Leon AC, Shear MK, Portera L, Klerman GL: Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992 27:78-82
16. Weissman MM: The Social Adjustment Self-Report Questionnaire, in Innovations in Clinical Practice: A Source Book, vol 5. Edited by Keller PA, Ritt LG. Sarasota, Fla, Professional Resource Exchange, 1986, pp 299-307
17. SAS User's Guide: Statistics, version 5.18. Cary, NC, SAS Institute, 1988
18. Keller MB, Hanks DL: Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:551-570
19. Mavissakalian MR, Perel JM: Imipramine-treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am I Psychiatry 1995; 152:673-682
20. Lesser IM, Lydiard RB, Antel F, Rubin RT, Ballenger JC, DuPont R: Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992; 149:1556-1562
21. Steiner M, Oakes R, Wheadon D, Gergel IP: Predictors of response to paroxetine therapy in the treatment of panic disorder, in 1996 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1996. pp 122-123
22. Mavissakalian M: Male and female agoraphobia: are they different? Behav Res Ther 1985; 23:469-471
23. Ballenger JC, Burrows G, DuPont RL Jr, Lesser JM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45:413-422
24. Schweizer E, Patterson W, Rickels K, Rosenthal M: Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150:1210-1215
25. Tollefson GD: Selective serotonin reuptake inhibitors, in Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 161-182
26. Amsterdam JD, Hornig-Rohan M, Maislin G: Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994; 55:394-400
27. Ballenger JC, Lydiard RB, Turner SM: Panic disorder and agora- phobia, in Treatments of Psychiatric Disorders, 2nd ed, vol 2. Edited by Gabbard GO. Washington, DC, American Psychiatric Press, 1995, pp 1421-1452
28. Mavissakalian MR, Perel JM: Imipramine dose-response relationship in panic disorder with agoraphobia: preliminary findings. Arch Gen Psychiatry 1989; 46:127-131
29. Noyes R Jr, Garvey MJ, Cook BL, Samuelson L: Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50:163-169
30. Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995; 10:45-49
31. Mavissakalian M: Differential efficacy between tricyclic antidepressants and behavior therapy of panic disorder, in Clinical Aspects of Panic Disorder: Frontiers of Clinical Neuroscience, vol 9. Edited by Ballenger JC, New York, Wiley-Liss, 1990, pp 195-209
32. Frank K, Kupfer DJ, Perel JM: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093-1099
33. Schatzberg AF, Ballenger JC: Decisions for the clinician in the treatment of panic disorder: when to treat, which treatment to use, and how long to treat. J Clin Psychiatry 1991; 52(Feb suppl):26-31
34. Burnham DB, Steiner M, Gergel IP, Oakes R, Bailer DC, Wheadon DE: Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: a double-blind study, in American College of Neuropsychopharmacology 34th Annual Meeting Abstracts of Panels and Posters. Nashville, Tenn, American College of Neuropsychopharmacology, 1995, p 201